Drug Trial Radar · NCT00141882
Memantine in Patients With Chronic Glaucoma
Last checked: Nov 20, 2026Latest source record: Nov 4, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,119
Actual
Start
Mar 1999
Primary completion
Jan 2006
Study completion Aug 2006
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized double-masked clinical trial of memantine in patients with glaucoma
Conditions
- Open-Angle Glaucoma
Interventions
memantineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression of glaucoma
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.